These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32162371)

  • 1. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply.
    Dulai PS
    Aliment Pharmacol Ther; 2020 Apr; 51(7):738-739. PubMed ID: 32162371
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?
    Verstockt B; Ferrante M
    Aliment Pharmacol Ther; 2020 Apr; 51(7):737-738. PubMed ID: 32162373
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: the road to elimination of viral hepatitis-another promising real-world experience.
    Abdel-Daim MM
    Aliment Pharmacol Ther; 2020 Jul; 52(2):405-406. PubMed ID: 32592247
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.
    Iborra M; Beltrán B; Nos P
    Aliment Pharmacol Ther; 2019 Sep; 50(5):600-601. PubMed ID: 31414541
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Radford-Smith GL; Hartnell F; Doecke JD
    Aliment Pharmacol Ther; 2017 Mar; 45(6):856-857. PubMed ID: 28211631
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: propensity score-handle with care. Authors' reply.
    Townsend T; Subramanian S
    Aliment Pharmacol Ther; 2021 Jan; 53(2):362-363. PubMed ID: 33368518
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
    Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
    Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply.
    Narula N; Reinisch W
    Aliment Pharmacol Ther; 2016 Oct; 44(7):772-3. PubMed ID: 27593431
    [No Abstract]   [Full Text] [Related]  

  • 9. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: post hoc analysis of SONIC trial--authors' reply.
    Colombel JF; Cornillie F; Bevelander G
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1211. PubMed ID: 25939462
    [No Abstract]   [Full Text] [Related]  

  • 11. Authors' reply to letters to the editor "model-based simulation to support the extended dosing regimens of atezolizumab".
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jul; 77(7):1067-1068. PubMed ID: 33237384
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
    Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M
    Aliment Pharmacol Ther; 2017 May; 45(9):1284. PubMed ID: 28370036
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.
    Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
    Aliment Pharmacol Ther; 2018 Sep; 48(5):578-579. PubMed ID: 30156321
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
    West J; Card TR; Crooks CJ
    Aliment Pharmacol Ther; 2022 Jul; 56(1):157. PubMed ID: 35689325
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply: To PMID 24530602.
    Regueiro M; Kip KE; Baidoo L; Swoger JM; Schraut W
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1407. PubMed ID: 24614332
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Eberhardson M; Söderling JK; Olén O
    Aliment Pharmacol Ther; 2018 Jan; 47(1):147-148. PubMed ID: 29226402
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply: To PMID 23811254.
    Osterman MT
    Clin Gastroenterol Hepatol; 2015 Jan; 13(1):210-1. PubMed ID: 25151256
    [No Abstract]   [Full Text] [Related]  

  • 20. THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.
    Kotze PG; Damião AO; Moraes AC
    Arq Gastroenterol; 2016; 53(1):3-4. PubMed ID: 27276096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.